Trace Neuroscience is a biopharmaceutical company on a mission to expand the promise of genomic medicine for people living with neurodegenerative diseases. With an initial focus on ALS, the company is developing novel therapies to restore UNC13A protein function to re-establish healthy communication between nerves and muscle cells.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 11/12/24 | $101,000,000 | Series A |
Atlas Venture GV RA Capital Management Third Rock Ventures  | undisclosed |
